Barclays Portfolio holdings
Barclays PLC, founded in 1690 by goldsmith bankers in London, is a British multinational financial institution headquartered in London, operating as one of the world’s oldest banks with a significant presence in investment banking, retail banking, and wealth management. Managing billions in assets, Barclays serves millions of customers globally through its retail arm (notably in the UK) and its investment banking division, which excels in trading, mergers and acquisitions, and capital markets, competing with Wall Street giants. The bank has navigated challenges like the 2008 financial crisis—opting for private funding over a government bailout—and has since focused on restructuring, digital innovation, and sustainable finance initiatives. With a rich history and a modern global footprint, Barclays remains a key player in both UK and international financial markets.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$1.39B |
| 2 |
iShares iBoxx $ Investment Grade Corporate Bond ETF
LQD
|
+$790M |
| 3 |
Invesco QQQ Trust
QQQ
|
+$648M |
| 4 |
iShares Russell 2000 ETF
IWM
|
+$411M |
| 5 |
Microsoft
MSFT
|
+$379M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street Communication Services Select Sector SPDR ETF
XLC
|
+$344M |
| 2 |
Consolidated Edison
ED
|
+$155M |
| 3 |
iShares MSCI United Kingdom ETF
EWU
|
+$154M |
| 4 |
Vanguard Total World Stock ETF
VT
|
+$146M |
| 5 |
State Street Energy Select Sector SPDR ETF
XLE
|
+$127M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 8.52% |
| 2 | Financials | 5.73% |
| 3 | Healthcare | 5.63% |
| 4 | Communication Services | 4.65% |
| 5 | Consumer Discretionary | 4.47% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
GHDX
2876
DELISTED
Genomic Health, Inc.
GHDX
| $2.02M | ﹤0.01% |
34,655
+6,452
| +23% | +$382K |
|
2877
CALL
BioMarin Pharmaceuticals
BMRN
$12.4B
| $2.01M | ﹤0.01% |
23,500
-1,200
| -5% | -$103K |
|
2878
CALL
Travere Therapeutics
TVTX
$5.78B
| $2.01M | ﹤0.01% |
+100,000
| New | +$1.97M |
|
|
WDR
2879
DELISTED
Waddell & Reed Financial, Inc.
WDR
| $2.01M | ﹤0.01% |
120,354
+46,601
| +63% | +$812K |
|
|
FISV
2880
PUT
Fiserv Inc
FISV
$27.9B
| $2.01M | ﹤0.01% |
22,000
+7,000
| +47% | +$613K |
|
2881
Bank of N.T. Butterfield & Son
NTB
$2.45B
| $2.01M | ﹤0.01% |
58,984
+23,363
| +66% | +$863K |
|
2882
CALL
SolarEdge
SEDG
$1.95B
| $2M | ﹤0.01% |
32,100
+11,000
| +52% | +$555K |
|
2883
CALL
CF Industries
CF
$17.3B
| $2M | ﹤0.01% |
42,900
+12,500
| +41% | +$542K |
|
2884
Apogee Enterprises
APOG
$908M
| $2M | ﹤0.01% |
46,044
+16,942
| +58% | +$662K |
|
|
ARGO
2885
DELISTED
Argo Group International Holdings, Ltd.
ARGO
| $2M | ﹤0.01% |
27,008
+14,137
| +110% | +$1.04M |
|
|
ENDP
2886
DELISTED
Endo International plc
ENDP
| $2M | ﹤0.01% |
485,695
+149,777
| +45% | +$945K |
|
|
NRE
2887
DELISTED
NorthStar Realty Europe Corp.
NRE
| $2M | ﹤0.01% |
121,659
-24,516
| -17% | -$415K |
|
2888
B&G Foods
BGS
$286M
| $2M | ﹤0.01% |
96,014
+33,998
| +55% | +$784K |
|
2889
RPM International
RPM
$15B
| $2M | ﹤0.01% |
32,655
+5,783
| +22% | +$341K |
|
2890
PUT
Edwards Lifesciences
EW
$51.7B
| $2M | ﹤0.01% |
32,400
-84,000
| -72% | -$5.08M |
|
2891
PUT
Fastenal
FAST
$59.5B
| $2M | ﹤0.01% |
122,400
-122,000
| -50% | -$2.01M |
|
|
NP
2892
DELISTED
Neenah, Inc. Common Stock
NP
| $2M | ﹤0.01% |
29,535
-7,453
| -20% | -$471K |
|
|
CEO
2893
CALL
DELISTED
CNOOC Limited
CEO
| $1.99M | ﹤0.01% |
11,700
-3,100
| -21% | -$540K |
|
2894
CALL
DaVita
DVA
$11.7B
| $1.99M | ﹤0.01% |
35,400
+14,000
| +65% | +$725K |
|
|
CMD
2895
DELISTED
Cantel Medical Corporation
CMD
| $1.99M | ﹤0.01% |
24,691
+18,406
| +293% | +$1.29M |
|
2896
CALL
Abercrombie & Fitch
ANF
$5B
| $1.99M | ﹤0.01% |
124,000
-13,000
| -9% | -$301K |
|
2897
Badger Meter
BMI
$4.03B
| $1.99M | ﹤0.01% |
33,319
-4,000
| -11% | -$222K |
|
2898
Copa Holdings
CPA
$5.8B
| $1.99M | ﹤0.01% |
20,393
-30,604
| -60% | -$2.71M |
|
|
CUK
2899
DELISTED
Carnival PLC
CUK
| $1.99M | ﹤0.01% |
43,914
+32,579
| +287% | +$1.67M |
|
|
KYNB
2900
PUT
Kyntra Bio
KYNB
$29.4M
| $1.99M | ﹤0.01% |
1,760
+1,720
| +4,300% | +$1.88M |
|
Similar funds
Barclays's Q2 2019 Portfolio in Review
As of Q2 2019, Barclays held 7,617 positions worth $163B, up 13% from $145B the previous quarter. Its ten largest holdings account for 25% of the portfolio.
Barclays deployed $14.2B of net new capital in Q2 2019, opening 457 new positions and adding to 3,922 existing holdings. Its largest new stake was Dow Inc: 2,580,874 shares worth $127M.
By sector, the portfolio is most concentrated in Technology at 8.5% of assets, up from 7.9% a quarter earlier, followed by Financials and Healthcare.
On the sell side, the largest reduction was State Street Communication Services Select Sector SPDR ETF, an estimated $344M trimmed.
- Barclays's largest Q2 2019 buy was Dow Inc: 2,580,874 shares worth $127M.
- Barclays added most to State Street SPDR S&P 500 ETF Trust in Q2 2019, an estimated $1.39B increase.
- Barclays's biggest Q2 2019 reduction was State Street Communication Services Select Sector SPDR ETF, cutting an estimated $344M.
- Barclays fully exited Bemis in Q2 2019, selling an estimated $33.4M.
- Barclays's ten largest holdings make up 25% of its $163B portfolio in Q2 2019.
- Barclays opened 457 new positions and closed 572 in Q2 2019.
- Barclays's portfolio value rose 13% quarter-over-quarter to $163B.
Based on Barclays's 13F filing for Q2 2019, filed 14 Aug 2019.